{"doi":"10.2139/ssrn.4671824","title":"Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B)","abstract":null,"journal":null,"year":null,"id":598669,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1534267,"name":"Lusine Yeghiazaryan","orcid":null,"position":1,"is_corresponding":false},{"id":364606,"name":"Christoph Stephan","orcid":"0000-0003-3777-9006","position":2,"is_corresponding":false},{"id":1534268,"name":"Kirsten Greve-Isdahl Mohn","orcid":null,"position":3,"is_corresponding":false},{"id":1534269,"name":"Antonio J Carcas","orcid":null,"position":4,"is_corresponding":false},{"id":1534270,"name":"Esperanza Romero Rodriguez","orcid":null,"position":5,"is_corresponding":false},{"id":1534271,"name":"José Marhuenda Moltó","orcid":null,"position":6,"is_corresponding":false},{"id":1534272,"name":"Itziar Vergara Micheltorena","orcid":null,"position":7,"is_corresponding":false},{"id":610018,"name":"Tobias Welte","orcid":"0000-0002-9947-7356","position":8,"is_corresponding":false},{"id":1534273,"name":"Birutė Zablockienė","orcid":null,"position":9,"is_corresponding":false},{"id":1534274,"name":"Murat Akova","orcid":null,"position":10,"is_corresponding":false},{"id":1534275,"name":"Ullrich Bethe","orcid":null,"position":11,"is_corresponding":false},{"id":1534276,"name":"Sarah Heringer","orcid":null,"position":12,"is_corresponding":false},{"id":1534277,"name":"Jon Salmanton-Garcia","orcid":null,"position":13,"is_corresponding":false},{"id":1534278,"name":"Julia Jeck","orcid":null,"position":14,"is_corresponding":false},{"id":1534279,"name":"Lea Tischmann","orcid":null,"position":15,"is_corresponding":false},{"id":1534281,"name":"Marouan Zarrouk","orcid":null,"position":16,"is_corresponding":false},{"id":1534282,"name":"Arnd Cüppers","orcid":null,"position":17,"is_corresponding":false},{"id":1534283,"name":"Lena  M. Biehl","orcid":null,"position":18,"is_corresponding":false},{"id":1534284,"name":"Jan H. Grothe","orcid":null,"position":19,"is_corresponding":false},{"id":1534285,"name":"Sibylle Mellinghoff","orcid":null,"position":20,"is_corresponding":false},{"id":1534286,"name":"Julia  Alexandra Nacov","orcid":null,"position":21,"is_corresponding":false},{"id":1534287,"name":"Julia  M. Neuhann","orcid":null,"position":22,"is_corresponding":false},{"id":839339,"name":"Rosanne Sprute","orcid":"0000-0003-2457-6437","position":23,"is_corresponding":false},{"id":361781,"name":"Jesús Frías","orcid":"0000-0001-9538-9677","position":24,"is_corresponding":false},{"id":1534288,"name":"Riya Negi","orcid":null,"position":25,"is_corresponding":false},{"id":1534289,"name":"Colette Gaillard","orcid":null,"position":26,"is_corresponding":false},{"id":1534290,"name":"Gurvin Saini","orcid":null,"position":27,"is_corresponding":false},{"id":1534291,"name":"Alejandro Abner Garcia Leon","orcid":null,"position":28,"is_corresponding":false},{"id":1258505,"name":"Patrick Mallon","orcid":"0000-0002-4337-6222","position":29,"is_corresponding":false},{"id":640810,"name":"Christine Lammens","orcid":"0000-0001-9424-3107","position":30,"is_corresponding":false},{"id":898747,"name":"An Hotterbeekx","orcid":"0000-0003-3356-4032","position":31,"is_corresponding":false},{"id":1534292,"name":"Katherine Loens","orcid":null,"position":32,"is_corresponding":false},{"id":1517064,"name":"Surbhi Malhotra-Kumar","orcid":null,"position":33,"is_corresponding":false},{"id":70963,"name":"Herman Goossens","orcid":null,"position":34,"is_corresponding":false},{"id":1534293,"name":"Samir Kumar-Singh","orcid":null,"position":35,"is_corresponding":false},{"id":1534294,"name":"Franz König","orcid":null,"position":36,"is_corresponding":false},{"id":38095,"name":"Martin Posch","orcid":"0000-0001-8499-8573","position":37,"is_corresponding":false},{"id":565707,"name":"Philipp Koehler","orcid":"0000-0002-7386-7495","position":38,"is_corresponding":false},{"id":1534295,"name":"Oliver  A. Cornely","orcid":null,"position":39,"is_corresponding":false},{"id":724781,"name":"Jannik Stemler","orcid":"0000-0001-9152-2469","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B)","abstract":"To assess the safety and immunogenicity of a fourth vaccination (second booster) in individuals aged ≥75 years.Participants were randomized to BNT162b2 (Comirnaty, 30 µg) or messenger RNA (mRNA)-1273 (Spikevax, 100 µg). The primary end point was the rate of two-fold antibody titer increase 14 days after vaccination, targeting the receptor binding domain (RBD) region of wild-type SARS-CoV-2. The secondary end points included changes in neutralizing activity against wild-type and 25 variants. Safety was assessed by monitoring solicited adverse events (AEs) for 7 days.A total of 269 participants (mean age 81 years, mRNA-1273 n = 135/BNT162b2 n = 134) were included. Two-fold anti-RBD immunoglobulin (Ig) G titer increase was achieved by 101 of 129 (78%) and 116 of 133 (87%) subjects in the BNT162b2 and the mRNA-1273 group, respectively (P = 0.054). A second booster of mRNA-1273 provided higher anti-RBD IgG geometric mean titer: 21.326 IU/mL (95% confidence interval: 18.235-24.940) vs BNT162b2: 15.181 IU/mL (95% confidence interval: 13.172-17.497). A higher neutralizing activity was noted for the mRNA-1273 group. The most frequent AE was pain at the injection site (51% in mRNA-1273 and 48% in BNT162b2). Participants in the mRNA-1273 group had less vaccine-related AEs (30% vs 39%).A second booster of either BNT162b2 or mRNA-1273 provided substantial IgG increase. Full-dose mRNA-1273 provided higher IgG levels and neutralizing capacity against SARS-CoV-2, with similar safety profile for subjects of advanced age.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21097893","pmcid":null,"openalex_id":"https://openalex.org/W4390119815","authors":[],"funders":[{"funder_name":"European Commission","grant_id":"101037867","title":"VACCELERATE - European Corona Vaccine Trial Accelerator Platform"}],"total_grants":1,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"green","license":"CC BY NC ND","oa_locations":[{"url":"http://dx.doi.org/10.2139/ssrn.4671824","host_type":"repository"},{"url":"http://dx.doi.org/10.2139/ssrn.4671824","host_type":"repository"},{"url":"https://doi.org/10.2139/ssrn.4671824","host_type":""},{"url":"https://doi.org/10.1016/j.ijid.2024.107161","host_type":""},{"url":"https://pubmed.ncbi.nlm.nih.gov/38992789","host_type":""},{"url":"http://hdl.handle.net/10486/720557","host_type":""},{"url":"https://dx.doi.org/10.1016/j.ijid.2024.107161","host_type":""},{"url":"https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14546","host_type":""},{"url":"https://doaj.org/article/f8eb2936f1bc47e680925b02612648b5","host_type":""},{"url":"https://hdl.handle.net/10486/720557","host_type":""},{"url":"https://repository.uantwerpen.be/docstore/d:irua:24737","host_type":""},{"url":"https://hdl.handle.net/10067/2074430151162165141","host_type":""},{"url":"https://repository.vu.lt/VU:ELABAPDB209331665&prefLang=en_US","host_type":""},{"url":"https://hdl.handle.net/11250/3191394","host_type":""}],"fields_of_study":["Radiopharmaceutical Chemistry and Applications","Cell Adhesion Molecules Research","Immunotherapy and Immune Responses","03 medical and health sciences","0303 health sciences"],"mesh_terms":[],"keywords":["Reactogenicity","Booster (rocketry)","Immunogenicity","Medicine","Booster dose","Pediatrics","Immunology","Engineering","Immunization","Male","COVID-19 Vaccines","Immunosenescence","Medicina","Immunization, Secondary","Infectious and parasitic diseases","RC109-216","Neutralizing antibodies","Antibodies, Viral","Immunogenicity, Vaccine","Humans","Booster vaccination","BNT162 Vaccine","Aged","Variants of concern","Aged, 80 and over","SARS-CoV-2","COVID-19","Advanced age","Antibodies, Neutralizing","Immunoglobulin G","Spike Glycoprotein, Coronavirus","Female","Human medicine","2019-nCoV Vaccine mRNA-1273"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":16,"sdg_label":"16. Peace & justice"},{"sdg_number":0,"sdg_label":"Zero hunger"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T16:05:41.104490Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}